These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

524 related items for PubMed ID: 19695010

  • 1. Comparative analysis of length of stay, total costs, and treatment success between intravenous moxifloxacin 400 mg and levofloxacin 750 mg among hospitalized patients with community-acquired pneumonia.
    Friedman H, Song X, Crespi S, Navaratnam P.
    Value Health; 2009; 12(8):1135-43. PubMed ID: 19695010
    [Abstract] [Full Text] [Related]

  • 2. A comparison of levofloxacin and moxifloxacin use in hospitalized community-acquired pneumonia (CAP) patients in the US: focus on length of stay.
    Schein J, Janagap-Benson C, Grant R, Sikirica V, Doshi D, Olson W.
    Curr Med Res Opin; 2008 Mar; 24(3):895-906. PubMed ID: 18419876
    [Abstract] [Full Text] [Related]

  • 3. Hospital visits and costs following outpatient treatment of CAP with levofloxacin or moxifloxacin.
    Signorovitch JE, Sheng Duh M, Sengupta A, Gu A, Grant R, Raut M, Mody SH, Schein J, Fisher AC, Ng D.
    Curr Med Res Opin; 2010 Feb; 26(2):355-63. PubMed ID: 19995325
    [Abstract] [Full Text] [Related]

  • 4. A cost-minimisation analysis comparing moxifloxacin with levofloxacin plus ceftriaxone for the treatment of patients with community-acquired pneumonia in Germany: results from the MOTIV trial.
    Lloyd A, Holman A, Evers T.
    Curr Med Res Opin; 2008 May; 24(5):1279-84. PubMed ID: 18358083
    [Abstract] [Full Text] [Related]

  • 5. Treatment failure rates and health care utilization and costs among patients with community-acquired pneumonia treated with levofloxacin or macrolides in an outpatient setting: a retrospective claims database analysis.
    Ye X, Sikirica V, Schein JR, Grant R, Zarotsky V, Doshi D, Benson CJ, Riedel AA.
    Clin Ther; 2008 Feb; 30(2):358-71. PubMed ID: 18343274
    [Abstract] [Full Text] [Related]

  • 6. A randomized trial comparing the cardiac rhythm safety of moxifloxacin vs levofloxacin in elderly patients hospitalized with community-acquired pneumonia.
    Morganroth J, Dimarco JP, Anzueto A, Niederman MS, Choudhri S, CAPRIE Study Group.
    Chest; 2005 Nov; 128(5):3398-406. PubMed ID: 16304291
    [Abstract] [Full Text] [Related]

  • 7. A cost-minimization analysis comparing azithromycin-based and levofloxacin-based protocols for the treatment of patients hospitalized with community-acquired pneumonia: results from the CAP-IN trial.
    Samsa GP, Matchar DB, Harnett J, Wilson J.
    Chest; 2005 Nov; 128(5):3246-54. PubMed ID: 16304269
    [Abstract] [Full Text] [Related]

  • 8. Community-Acquired Pneumonia Recovery in the Elderly (CAPRIE): efficacy and safety of moxifloxacin therapy versus that of levofloxacin therapy.
    Anzueto A, Niederman MS, Pearle J, Restrepo MI, Heyder A, Choudhri SH, Community-Acquired Pneumonia Recovery in the Elderly Study Group.
    Clin Infect Dis; 2006 Jan 01; 42(1):73-81. PubMed ID: 16323095
    [Abstract] [Full Text] [Related]

  • 9. Moxifloxacin monotherapy is effective in hospitalized patients with community-acquired pneumonia: the MOTIV study--a randomized clinical trial.
    Torres A, Garau J, Arvis P, Carlet J, Choudhri S, Kureishi A, Le Berre MA, Lode H, Winter J, Read RC, MOTIV (MOxifloxacin Treatment IV) Study Group.
    Clin Infect Dis; 2008 May 15; 46(10):1499-509. PubMed ID: 18419482
    [Abstract] [Full Text] [Related]

  • 10. A novel method of estimating cost of therapy by using patient population characteristics: analysis of fluoroquinolones in various populations with different distributions of renal function.
    Enzweiler KA, Bosso JA, White RL.
    Pharmacotherapy; 2003 Jul 15; 23(7):925-32. PubMed ID: 12885105
    [Abstract] [Full Text] [Related]

  • 11. Moxifloxacin versus levofloxacin for treatment of acute rhinosinusitis: a retrospective database analysis of treatment duration, outcomes, and charges.
    Keating KN, Friedman HS, Perfetto EM.
    Curr Med Res Opin; 2006 Feb 15; 22(2):327-33. PubMed ID: 16466604
    [Abstract] [Full Text] [Related]

  • 12. An economic and outcomes assessment of first-line monotherapy in the treatment of community-acquired pneumonia within managed care.
    Skrepnek GH, Armstrong EP, Malone DC, Ramachandran S.
    Curr Med Res Opin; 2005 Feb 15; 21(2):261-70. PubMed ID: 15801997
    [Abstract] [Full Text] [Related]

  • 13. Cost analyses of community-acquired pneumonia from the hospital perspective.
    Bauer TT, Welte T, Ernen C, Schlosser BM, Thate-Waschke I, de Zeeuw J, Schultze-Werninghaus G.
    Chest; 2005 Oct 15; 128(4):2238-46. PubMed ID: 16236880
    [Abstract] [Full Text] [Related]

  • 14. Experiences at a large teaching hospital with levofloxacin for the treatment of community-acquired pneumonia.
    Clark LC, Davis CW.
    Am J Health Syst Pharm; 2000 Nov 15; 57 Suppl 3():S10-3. PubMed ID: 11098314
    [Abstract] [Full Text] [Related]

  • 15. An economic evaluation of sequential i.v./po moxifloxacin therapy compared to i.v./po co-amoxiclav with or without clarithromycin in the treatment of community-acquired pneumonia.
    Drummond MF, Becker DL, Hux M, Chancellor JV, Duprat-Lomon I, Kubin R, Sagnier PP.
    Chest; 2003 Aug 15; 124(2):526-35. PubMed ID: 12907538
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Antibiotic treatment patterns, costs, and resource utilization among patients with community acquired pneumonia: a US cohort study.
    Llop CJ, Tuttle E, Tillotson GS, LaPlante K, File TM.
    Hosp Pract (1995); 2017 Feb 15; 45(1):1-8. PubMed ID: 28064542
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Clinical implications of 750 mg, 5-day levofloxacin for the treatment of community-acquired pneumonia.
    File TM, Milkovich G, Tennenberg AM, Xiang JX, Khashab MM, Zadeikis N.
    Curr Med Res Opin; 2004 Sep 15; 20(9):1473-81. PubMed ID: 15383197
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 27.